Form D · Biotechnology
Miragen Therapeutics, Inc.
Boulder, CO · CIK 0001417827
Offering snapshot reported Feb 14, 2017 · SEC filing
- Reported sold
- $40.7M Offering amount: $40.7M
- Investors reported
- 25 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Feb 13, 2017 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Feb 14, 2017 | Initial | $40,703,067 | No comparison | 25 | SEC filing |
| Nov 12, 2015 | Initial | $24,968,495 | No comparison | 34 | SEC filing |
| Feb 17, 2015 | Initial | $8,499,962 | No comparison | 29 | SEC filing |
| Jun 26, 2014 | Amendment | $12,999,906 | $6,999,960vs Apr 24, 2012 | 29 | SEC filing |
| Apr 24, 2012 | Initial | $5,999,946 | No comparison | 29 | SEC filing |
| Jan 3, 2012 | Amendment | $6,000,000 | $3,000,000vs Sep 21, 2010 | 24 | SEC filing |
| Sep 21, 2010 | Initial | $3,000,000 | No comparison | 24 | SEC filing |
| May 27, 2009 | Initial | $52,983 | No comparison | Not reported | SEC filing |
| May 27, 2009 | Amendment | $11,999,997 | No comparison | Not reported | SEC filing |
| Jan 28, 2009 | Paper | Not reported | No comparison | Not reported | SEC filing |
| May 29, 2008 | Paper | Not reported | No comparison | Not reported | SEC filing |
| Nov 6, 2007 | Paper | Not reported | No comparison | Not reported | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.2M
- Finders' fees
- $0
- Form D file number
- 021-280608
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| Wedbush Securities Inc. | 877 | Wedbush Securities Inc. · CRD 877 |
Source: Form D, filed Feb 14, 2017. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Bruce L. Booth | Director |
| Marvin H Caruthers | Director |
| John W. Creecy | Director |
| Thomas E. Hughes | Director |
| Kevin Koch | Director |
| Kyle A. Lefkoff | Director |
| Jason A Leverone | Executive |
| Adam S Levy | Executive |
| William S. Marshall | Director, Executive |
| Christopher J Morl | Executive |
| Joshua Resnick | Director |
| David Rodman | Executive |
| Paul D. Rubin | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
6200 Lookout Road #100
Boulder, CO, 80301
Boulder, CO, 80301